Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07363694 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase 2 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,156
- Enrollment target
NCT07363694 is a Phase 2 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 1,156 participants.
The verdict
NCT07363694, a Phase 2 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,156 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 35 to 80 years old * Have had moderate-to-severe COPD for at least 12 months * Have a documented history of at least 2 moderate or severe exacerbations within the last 12 months * Have been continuously taking their regular maintenance treatment(s) for COPD over at least 6 months at a stable dose for 3 months All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 24 weeks for the Phase 2 part and 52 weeks for the Phase 3 part. We will compare the results of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective. Participants who will be involved in the Phase 2 part of the study for about 40 weeks. During this time, they will have 11 visits at the study clinic. Participants who will be involved in the Phase 3 part of the study for about 68 weeks. During this time, they will have 18 visits at the study clinic.
Interventions
- DRUG Placebo
- DRUG PF-07275315 dose 1
- DRUG PF-07275315-dose 2
- DRUG PF-07275315-dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,156 participants |
| Start Date | 2026-02-11 |
| Est. Completion | 2031-01-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07363694
The ClinicalTrials.gov registry entry for NCT07363694 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07363694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07363694 about?
NCT07363694 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease". The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected. This st...
What is the current status of trial NCT07363694?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,156 participants. The study started on 2026-02-11. Estimated completion is 2031-01-16.
What interventions are being tested in trial NCT07363694?
The interventions under investigation include: Placebo (DRUG), PF-07275315 dose 1 (DRUG), PF-07275315-dose 2 (DRUG), PF-07275315-dose 3 (DRUG).
Who is sponsoring clinical trial NCT07363694?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.